ASH Flash 1: Ponatinib Doses as low as 10 mg were still associated with disease control overall.

From the American Society of Hematology:

3153 High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: Poster II

Conclusions:

BARD enables a detailed exploration of dose-response relationships in CP-CML.  In newly diagnosed patients, ponatinibdoses as low as 15 mg induced more rapid decreases in BCR-ABL levels than 400 mg imatinib.  Consistent with the possibility that sequential treatment with TKIs increases the degree of BCR-ABL independence, the magnitude of BCR-ABL decreases induced by ponatinib in heavily pretreated patients was reduced compared with newly diagnosed patients. Nonetheless, ponatinib doses as low as 10 mg were still associated with disease control overall.  These analyses will help inform the design of future studies aimed at optimizing the benefit/risk of ponatinib treatment for patients with CML.